Why is "Amyloid cardiomyopathy" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-08-06 04:41:48
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Amyloid_cardiomyopathy entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-08-06 and was most recently seen on 2026-08-06.
Wikipedia Overview
Amyloid cardiomyopathy is a condition resulting in the death of part of the myocardium. It is associated with the systemic production and release of many amyloidogenic proteins, especially immunoglobulin light chain or transthyretin (TTR). It can be characterized by the extracellular deposition of amyloids, foldable proteins that stick together to build fibrils in the heart.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Clinical Burden and Diagnostic Challenges - The American Journal of Managed Care® (AJMC®)
-
Understanding the heart disease aspect of transthyretin amyloid cardiomyopathy (ATTR-CM) - Mayo Clinic Press
-
Fibroblast growth factor 23 is associated with cardiac disease severity in transthyretin amyloid cardiomyopathy - Nature
-
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy - BioSpace
-
Acoramidis Significantly Improves Quality of Life in Amyloid Cardiomyopathy: JAMA - Medical Dialogues
-
Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy - AstraZeneca
-
Catheter Ablation and Device Therapy in Patients With Transthyretin Amyloid Cardiomyopathy: A Review of Non-Pharmacological Therapy - Wiley Online Library
-
New Concise Clinical Guidance Addresses Evaluation and Management of ATTR-CM - American College of Cardiology
-
Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
Increase in Serum Transthyretin After Tafamidis Is Associated With Improved Survival in Transthyretin Amyloid Cardiomyopathy - JACC Journals
-
Diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM)? Here's what to know about this rare heart condition - Mayo Clinic Press
-
Applicability of phase 3 trial selection criteria to real-world transthyretin amyloid cardiomyopathy patients - Nature
-
Pathology-Based Validation of Quantitative SPECT/CT in Patients With Suspected Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
New Proposed Criteria For Monitoring Disease Progression in ATTR-CM - American College of Cardiology
-
Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States - American Heart Association Journals
-
Anti-Fibril Depleters: The Dawn of a New Treatment Era in Transthyretin Amyloid Cardiomyopathy? - American Heart Association Journals
-
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial - American Heart Association Journals
-
Anti-Fibril Depleters: The Dawn of a New Treatment Era in Transthyretin Amyloid Cardiomyopathy? - American Heart Association Journals
-
Cardiac amyloidosis in the spotlight at Heart Failure 2026 - Cardiovascular Business
-
Transthyretin amyloid cardiomyopathy: Acoramidis reduces the risk of heart failure worsening by 41%. - lamilano.it
-
Updated ATTR-CM Criteria Standardize Disease Progression Monitoring - The American Journal of Managed Care® (AJMC®)
-
Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy - Frontiers
-
What to know about ATTR-CM and treatment options - Managed Healthcare Executive
-
Acoramidis Reduces Mortality in Amyloid Cardiomyopathy Up to 42 Months: Study - Medical Dialogues
-
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy - The New England Journal of Medicine
-
Transthyretin Amyloid Cardiomyopathy: What Is It and How Rare Is It Really? - MedPage Today
-
Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
Trends in Diagnostic Testing in Medicare Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy - Frontiers
-
Amvuttra Gains Approval for Transthyretin Amyloid Cardiomyopathy - MPR - Medical Professionals Reference
-
Early Diagnosis of ATTR-CM - Medscape
-
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy - The New England Journal of Medicine
-
Phase III Trial of Acoramidis for Transthyretin Amyloid Cardiomyopathy Provides Positive, High-level Results - Applied Clinical Trials Online
-
Geisinger Enrolls First Patient in Amyloid Cardiomyopathy Trial - dicardiology.com
-
Novel gene-editing therapy shows promise for patients with transthyretin amyloid cardiomyopathy - www.heart.org
-
Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy - Nature
-
Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy. - Physician's Weekly
-
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy | Circulation - American Heart Association Journals
-
Nexiguran ziclumeran reduces serum TTR levels in transthyretin amyloid cardiomyopathy - 2minutemedicine.com
-
VisualAbstract: Acoramidis is an efficacious treatment for transthyretin amyloid cardiomyopathy compared to placebo - 2minutemedicine.com
-
Substrate Characterization and Outcomes of Ventricular Tachycardia Ablation in Amyloid Cardiomyopathy: A Multicenter Study - American Heart Association Journals
-
Right Ventricular Bone-Avid Tracer Uptake: A Novel Risk Marker in Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
Tafamidis attenuates the decline of cardiac function in patients with transthyretin amyloid cardiomyopathy - 2minutemedicine.com
-
VisualAbstract: Antibody NI006 for treatment of transthyretin amyloid cardiomyopathy caused no serious adverse events - 2minutemedicine.com
-
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy - PR Newswire
-
Acoramidis may improve cardiac mass, function in transthyretin amyloid cardiomyopathy - healio.com
-
124I-Evuzamitide PET/CT Diagnosis of Wild-Type Transthyretin Amyloid Cardiomyopathy in a Woman With Negative Diagnostic Evaluation | Circulation: Cardiovascular Imaging - American Heart Association Journals
-
Biochemical and biophysical properties of a rare TTRA81V mutation causing mild transthyretin amyloid cardiomyopathy - Wiley Online Library
-
Phase 3 data show acoramidis improves outcomes in transthyretin amyloid cardiomyopathy - healio.com
-
Long-Term Outcomes of Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy in Two Patients - JACC Journals
-
A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy - Nature
-
124I-Evuzamitide PET/CT Diagnosis of Wild-Type Transthyretin Amyloid Cardiomyopathy in a Woman With Negative Diagnostic Evaluation | Circulation: Cardiovascular Imaging - American Heart Association Journals
-
Bone tracers for transthyretin amyloid cardiomyopathy: are [99mTc]Tc-DPD and [99mTc]Tc-HMDP truly equivalent? - medRxiv
-
Eplontersen Gains FDA Fast Track Designation for Transthyretin-Mediated Amyloid Cardiomyopathy - NeurologyLive
-
No. 3 Medical Innovation for 2020: Inaugural Medication for Transthyretin Amyloid Cardiomyopathy - consultqd.clevelandclinic.org
-
Transthyretin amyloid cardiomyopathy: Literature review and red-flag symptom clusters for each cardiology specialty - Wiley Online Library
-
Antibody NI006 for treatment of transthyretin amyloid cardiomyopathy caused no serious adverse events - 2minutemedicine.com
-
Durable Mechanical Circulatory Support in Patients With Amyloid Cardiomyopathy: - American Heart Association Journals
-
Advancing diagnostics and therapy in transthyretin amyloid cardiomyopathy - Holcman - 2025 - ESC Heart Failure - Wiley Online Library
-
Transthyretin amyloid cardiomyopathy in aortic stenosis patients scheduled for transcatheter aortic valve implantation - Wiley Online Library
-
Understanding Your Treatment Options for Transthyretin Amyloid Cardiomyopathy - Healthgrades Health Library
-
Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study - Wiley Online Library
-
Simple score developed to predict increased risk of transthyretin amyloid cardiomyopathy in patients with heart failure with preserved ejection fraction - 2minutemedicine.com
-
Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial - American Heart Association Journals
-
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study - Wiley Online Library
-
‘Across the board’ benefits seen with acoramidis for transthyretin amyloid cardiomyopathy - healio.com
-
Prevalence of Atrial Fibrillation and Thromboembolic Risk in Wild-Type Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
Why Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Can Be Misdiagnosed - Healthgrades Health Library
-
Kidney Decline: A Key Predictor of Transthyretin Amyloid Cardiomyopathy Mortality - emjreviews.com
-
Acoramidis in Transthyretin Amyloid Cardiomyopathy - The New England Journal of Medicine
-
PFIZER CALLS FOR MORE AWARENESS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) - A RARE, LIFE-THREATENING DISEASE - PR Newswire
-
Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score - Wiley Online Library
-
A Breakthrough With a Burden: Access, Affordability, and the Future of ATTR-CM Therapy - JACC Journals
-
Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
AHA Guidance for the Diagnosis and Management of Transthyretin Amyloid Cardiomyopathy - The Cardiology Advisor
-
Amyloid cardiomyopathy drug Vyndamax to get health insurance from March - koreabiomed.com
-
Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy - TCTMD.com
-
Tafamidis confers 5-year survival benefit in transthyretin amyloid cardiomyopathy - healio.com
-
Blood test may help identify patients at risk for transthyretin amyloid cardiomyopathy - news-medical.net
-
First Treatments for Transthyretin Amyloid Cardiomyopathy Get FDA Approval - The Cardiology Advisor
-
Prevalence of Atrial Fibrillation and Thromboembolic Risk in Wild-Type Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine - dicardiology.com
-
Your Guide to Vyndamax for Transthyretin Amyloid Cardiomyopathy - HealthCentral
-
How to Spot and Manage the Complications From ATTR-CM - HealthCentral
-
Positive high-level results from Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) showed consistency with global ATTRibute-CM Phase III trial - AstraZeneca
-
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy - PR Newswire
-
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review - Wiley Online Library
-
Cardiopulmonary exercise testing predicts prognosis in amyloid cardiomyopathy: a systematic review and meta-analysis - Wiley Online Library
-
9 Things Your Doctor Wants You to Know About ATTR-CM - HealthCentral
-
Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries - Wiley Online Library
-
FDA Approves New Treatment for Transthyretin Amyloid Cardiomyopathy - Pharmacy Times
-
Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy - Wiley Online Library
-
Making tafamidis cost-effective for TTR amyloid cardiomyopathy may require 93% price reduction - healio.com
-
FDA approves Stanford Medicine-developed drug that treats rare heart disease - Stanford Medicine
-
Amyloid Cardiomyopathy - healio.com
-
Understanding Changes in Functional Capacity After TTR Stabilization in Patients With Transthyretin Cardiac Amyloidosis - American Heart Association Journals
-
Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild‐Type Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
Healthy Habits for Better Living With ATTR-CM - HealthCentral
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.